Search

Displaying results 2891 - 2900 of 6835 in total
  1. Drug

    Acetazolamide

    go.drugbank.com/drugs/DB00819
    ApprovedInvestigationalVet approved

    Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition

  2. Drug

    Halcinonide

    go.drugbank.com/drugs/DB06786
    ApprovedWithdrawn

    Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. … Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.

    International brands: Ha Le Te
  3. Drug

    Ritonavir

    go.drugbank.com/drugs/DB00503
    ApprovedInvestigational

    Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug … Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors

  4. Drug

    Vidarabine

    go.drugbank.com/drugs/DB00194
    ApprovedWithdrawn

    It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the

  5. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils. … [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo.

  6. Drug

    Apixaban

    go.drugbank.com/drugs/DB06605
    ApprovedInvestigational

    Apixaban was approved by the FDA on December 28, 2012[L6043].

  7. Drug

    Alanine

    go.drugbank.com/drugs/DB00160
    ApprovedInvestigationalNutraceutical

    It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.

  8. Drug

    Azatadine

    go.drugbank.com/drugs/DB00719
    ApprovedWithdrawn

    Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.

    Mixtures: CO-TYLENOL
  9. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. … approval was based on results from the Phase 3 PERSEUS study, which demonstrated significant improvement in progression-free survival and higher rates of minimal residual disease (MRD) negativity compared to

  10. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.